IL2 and myelodysplastic syndrome: The immunomodulatory agents lenalidomide and pomalidomide were similarly shown to potentiate anti-leukemic and anti-MDS NK responses through several mechanisms including increased IL-2 and IL-15 production and increased expression of activating receptors (107, 108).